Novozymes A/S
CSE:NZYM B
Intrinsic Value
Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. [ Read More ]
The intrinsic value of one NZYM B stock under the Base Case scenario is 124.83 DKK. Compared to the current market price of 403 DKK, Novozymes A/S is Overvalued by 69%.
Valuation Backtest
Novozymes A/S
Run backtest to discover the historical profit from buying and selling NZYM B stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Novozymes A/S
Current Assets | 9.5B |
Cash & Short-Term Investments | 1.2B |
Receivables | 4.3B |
Other Current Assets | 4B |
Non-Current Assets | 18.9B |
Long-Term Investments | 267m |
PP&E | 12.3B |
Intangibles | 4.5B |
Other Non-Current Assets | 1.8B |
Current Liabilities | 7.3B |
Accounts Payable | 1.6B |
Other Current Liabilities | 5.6B |
Non-Current Liabilities | 7.2B |
Long-Term Debt | 4.6B |
Other Non-Current Liabilities | 2.6B |
Earnings Waterfall
Novozymes A/S
Revenue
|
17.9B
DKK
|
Cost of Revenue
|
-8.2B
DKK
|
Gross Profit
|
9.7B
DKK
|
Operating Expenses
|
-5.3B
DKK
|
Operating Income
|
4.5B
DKK
|
Other Expenses
|
-1.4B
DKK
|
Net Income
|
3B
DKK
|
Free Cash Flow Analysis
Novozymes A/S
NZYM B Profitability Score
Profitability Due Diligence
Novozymes A/S's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Novozymes A/S's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
NZYM B Solvency Score
Solvency Due Diligence
Novozymes A/S's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Novozymes A/S's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NZYM B Price Targets Summary
Novozymes A/S
According to Wall Street analysts, the average 1-year price target for NZYM B is 405.07 DKK .
Shareholder Return
NZYM B Price
Novozymes A/S
Average Annual Return | 9.12% |
Standard Deviation of Annual Returns | 35.93% |
Max Drawdown | -47% |
Market Capitalization | 165.6B DKK |
Shares Outstanding | 410 872 446 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. The firm operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. The company develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.
Officers
The intrinsic value of one NZYM B stock under the Base Case scenario is 124.83 DKK.
Compared to the current market price of 403 DKK, Novozymes A/S is Overvalued by 69%.